Learn more about how our cTA platform can precisely report novel endpoints while interpreting context of the surrounding tissue.
- We leverage proprietary algorithms specifically designed and validated to assess biomarker expression in muscle tissue samples.
- Our quantifiable, reproducible data and experienced consultative team provides understanding of high complex staining, enabling critical decisions to be made with confidence.
Whole slide analysis of muscle sections
Muscular Disease Research & Clinical Trial News
Stay up to date on the latest developments in muscular diseases and therapeutic advances.
- Muscular Dystrophy News Today article: MuscleMap Automated Dystrophin Analysis Tool Can Help in DMD Assessment, Study Suggests
- Flagship's Digital Tissue Image Analysis Approach Validated in Assessment of Dystrophin Muscle Biopsies; Findings Published in Archives of Pathology & Laboratory Medicine
- Summit Therapeutics R&D Day
- Summit Highlight Biomarker Validation Data at 22nd World Muscle Society Congress
- Summit Therapeutics shares DMD Data
- Sarepta Therapeutics to Present at the 22nd International Annual Congress of the World Muscle Society
- Flagship Supports Summit Therapeutics advancement of DMD therapies
- Solid Biosciences Announces Agreement with Flagship to Support Development of Gene Therapy for DMD.
Multi-analyte analysis of morphological features of individual muscle fibers
Find out more about industry leaders and patient advocacy groups in muscular diseases and how to be involved.